Inferra AI / Company / KMTS
Kestra Medical Technologies, Ltd..
KMTS · Health Care
Last earnings Sep 14, 2026
Key results
Generated revenuequarter
$19.4 million
Financial Highlights • Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period.
SEC original ↗Kestra Medical Technologies, Ltd.. — Earnings release (8-K exhibit)EX-99Sep 11, 2025
Expanded gross marginquarter
45.7%
• Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period.
SEC original ↗Kestra Medical Technologies, Ltd.. — Earnings release (8-K exhibit)EX-99Sep 11, 2025
Revenuequarter
50%
“We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter,” said Brian Webster, President and CEO.
SEC original ↗Kestra Medical Technologies, Ltd.. — Earnings release (8-K exhibit)EX-99Sep 11, 2025
Total revenuequarter
$19.4 million
” First Quarter Fiscal 2026 Financial Results • Total revenue was $19.4 million, an increase of 52% compared to the prior year period.
SEC original ↗Kestra Medical Technologies, Ltd.. — Earnings release (8-K exhibit)EX-99Sep 11, 2025
Gross marginquarter
45.7%
• Gross margin expanded to 45.7% compared to 32.9% in the prior year period, driven by volume leverage and a higher mix of in-network patients.
SEC original ↗Kestra Medical Technologies, Ltd.. — Earnings release (8-K exhibit)EX-99Sep 11, 2025
AI analysis
Q1 FY2026 · reported Sep 11, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
GAAP gross margin
Percent of revenue, as stated
EX-99 · Sep 11, 2025 Margin values as stated in the release.
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Sep 11, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q1 FY2026 | Prior qtr | Year ago |
|---|---|---|---|
| Generated revenue | $19.4 million | — | — |
| Expanded gross margin | 45.7% | — | 32.9% |
| Revenue | 50% | — | — |
| Total revenue | $19.4 million | — | — |
| Gross margin | 45.7% | — | 32.9% |
Guidance · company-stated
Direction: Raised
“• Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25.”
“Fiscal Year 2026 Revenue Guidance Kestra is increasing its FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25.”
Classified from the release's primary full-year outlook statement.
Margin
Capital allocation
Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, technology developments, financing and investment plans, dividend policy, competitive position, industry and regulatory environment, potential growth opportunities and the effects of competition.
Based on the Company s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund the Company s planned operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these financial statements.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +353.6% computed from stated figures
Event summary
Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “• Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25.”
Revenue: “Fiscal Year 2026 Revenue Guidance Kestra is increasing its FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25.”
Revenue — Raised (“Increased”)
“• Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25.”
Revenue — Raised (“increasing”)
“Fiscal Year 2026 Revenue Guidance Kestra is increasing its FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, technology developments, financing and investment plans, dividend policy, competitive position, industry and regulatory environment, potential growth opportunities and the effects of competition.
SEC original ↗Kestra Medical Technologies, Ltd.. — 10-Q Quarterly report10-QSep 14, 2026
Based on the Company s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund the Company s planned operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these financial statements.
SEC original ↗Kestra Medical Technologies, Ltd.. — 10-Q Quarterly report10-QSep 14, 2026
However, the Company may experience lower than expected cash generated from operating activities or greater than expected capital expenditures, cost of revenue or operating expenses and may require additional funding to execute on its growth plans, which may include funding raised through future equity and debt financings.
SEC original ↗Kestra Medical Technologies, Ltd.. — 10-Q Quarterly report10-QSep 14, 2026
If the estimated fair value of a marketable debt security is below its amortized cost basis, the Company evaluates whether it is more likely than not that the Company will be required to sell the security before its anticipated recovery in market value and whether credit losses exist for the related securities.
SEC original ↗Kestra Medical Technologies, Ltd.. — 10-Q Quarterly report10-QSep 14, 2026
Debt Issuance Costs Debt issuance costs related to term loan debt are recognized as a reduction to the related debt balance in the accompanying condensed consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method.
SEC original ↗Kestra Medical Technologies, Ltd.. — 10-Q Quarterly report10-QSep 14, 2026
Debt issuance costs associated with delayed draw term loans are capitalized within other long-term assets on the unaudited interim condensed consolidated balance sheets and are amortized to interest expense over the term of the related debt.
SEC original ↗Kestra Medical Technologies, Ltd.. — 10-Q Quarterly report10-QSep 14, 2026
Strategy & priorities
As we progress on our journey to category leadership, we remain focused on both market share capture and growing the wearable defibrillator market, while executing on our commitments to patients and their prescribers.
SEC original ↗Kestra Medical Technologies, Ltd.. — Earnings release (8-K exhibit)EX-99Sep 11, 2025
Adjusted EBITDA, which is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, share-based compensation expense, and non-recurring new public company costs, is presented because management believes it allows investors to view the Company’s performance in a manner similar to the method used by management to evaluate the Company’s performance for both strategic and annual operating planning.
SEC original ↗Kestra Medical Technologies, Ltd.. — Earnings release (8-K exhibit)EX-99Sep 11, 2025
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products.
SEC original ↗Kestra Medical Technologies, Ltd.. — Earnings release (8-K exhibit)EX-99Sep 11, 2025
is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected.
SEC original ↗Kestra Medical Technologies, Ltd.. — Earnings release (8-K exhibit)EX-99Sep 11, 2025
Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, technology developments, financing and investment plans, dividend policy, competitive position, industry and regulatory environment, potential growth opportunities and the effects of competition.
SEC original ↗Kestra Medical Technologies, Ltd.. — 10-Q Quarterly report10-QSep 14, 2026
Risks & headwinds
Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part.
SEC original ↗Kestra Medical Technologies, Ltd.. — Earnings release (8-K exhibit)EX-99Sep 11, 2025
Kestra’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.
SEC original ↗Kestra Medical Technologies, Ltd.. — Earnings release (8-K exhibit)EX-99Sep 11, 2025
Legal Proceedings 34 Item 1A.
SEC original ↗Kestra Medical Technologies, Ltd.. — 10-Q Quarterly report10-QSep 14, 2026
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
SEC original ↗Kestra Medical Technologies, Ltd.. — 10-Q Quarterly report10-QSep 14, 2026
" Given these uncertainties, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate.
SEC original ↗Kestra Medical Technologies, Ltd.. — 10-Q Quarterly report10-QSep 14, 2026
Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.
SEC original ↗Kestra Medical Technologies, Ltd.. — 10-Q Quarterly report10-QSep 14, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
21 documentsEarnings releases
9 documentsPresentations
0 documentsNo presentations for Kestra Medical Technologies, Ltd.. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Kestra Medical Technologies, Ltd.. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.